Revenues for the three months ended September 30, 2015 increased $12.5 million, or 670.1%, to $14.4 million, from $1.9 million for the comparable prior year period. Our net loss for the three months ended September 30, 2015 was $0.9 million as compared with a net loss of $5.4 million for the comparable prior year period, a decrease of $4.5 million.
Earnings before interest, taxes, depreciation and amortization, stock-based compensation, warrants issued to non-employees and common stock issued to consultants ("Adjusted EBITDA"), which is reconciled to net income in this press release, was income of $2,139,000 in the three months ended September 30, 2015, compared to a loss of $2,328,000 in the comparable prior year period.
"We are extremely pleased to announce that, during the recently concluded quarter, we successfully completed the fulfillment of the ECAC orders, resulting in the achievement of record quarterly revenues of $14.4 million and adjusted EBITDA income of $2.1 million," commented Dr. William McGann, CEO of Implant Sciences. "The production ramp we experienced was unprecedented and the focus necessary to fulfill our customer demand necessitated new processes and procedures that we believe will continue to yield long-term benefits. In prior earnings releases and conference calls, we discussed our need to become self-sufficient and generate the cash flow required from internal operations. During the first quarter, we successfully self-funded the significant working capital required to deliver the record revenues being reported today."